XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Basis of Presentation (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2015
USD ($)
Mar. 31, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Number of segments | segment   1  
Cash and investments   $ 89,704 $ 116,689
Accumulated deficit   (741,001) (712,930)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Accounts receivable   4,394 502
Collaborators      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Accounts receivable   3,800 $ 500
Commercial customers      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Accounts receivable   $ 600  
Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payment terms   30 days  
Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payment terms   60 days  
AstraZeneca      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Aggregate cost of revenue recognized   $ 11,700  
AstraZeneca | AZ Termination Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percentage of royalty revenue 10.00%    
Percentage of non-royalty revenue 20.00%    
Maximum potential payment per agreement $ 75,000